299 related articles for article (PubMed ID: 11530998)
1. Suppression of renal disease and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus (SLE) by chenodeoxycholic acid.
Suwannaroj S; Lagoo A; McMurray RW
Lupus; 2001; 10(8):562-7. PubMed ID: 11530998
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus.
McMurray RW; Elbourne KB; Lagoo A; Lal S
J Rheumatol; 1998 Dec; 25(12):2364-70. PubMed ID: 9858431
[TBL] [Abstract][Full Text] [Related]
3. Antioxidants suppress mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus (SLE).
Suwannaroj S; Lagoo A; Keisler D; McMurray RW
Lupus; 2001; 10(4):258-65. PubMed ID: 11341102
[TBL] [Abstract][Full Text] [Related]
4. The Systemic Activation of Programmed Death 1-PD-L1 Axis Protects Systemic Lupus Erythematosus Model from Nephritis.
Liao W; Zheng H; Wu S; Zhang Y; Wang W; Zhang Z; Zhou C; Wu H; Min J
Am J Nephrol; 2017; 46(5):371-379. PubMed ID: 29069649
[TBL] [Abstract][Full Text] [Related]
5. The beneficial effects of treatment with all-trans-retinoic acid plus corticosteroid on autoimmune nephritis in NZB/WF mice.
Nozaki Y; Yamagata T; Yoo BS; Sugiyama M; Ikoma S; Kinoshita K; Funauchi M; Kanamaru A
Clin Exp Immunol; 2005 Jan; 139(1):74-83. PubMed ID: 15606616
[TBL] [Abstract][Full Text] [Related]
6. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
Werwitzke S; Trick D; Sondermann P; Kamino K; Schlegelberger B; Kniesch K; Tiede A; Jacob U; Schmidt RE; Witte T
Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887
[TBL] [Abstract][Full Text] [Related]
7. Effect of E6060 [4-{5-[7-fluoro-4-(trifluoromethyl)benzo[b]furan-2-yl]-1H-2-pyrrolyl}benzoic acid], a novel subtype-selective retinoid, on lupus-like nephritis in female (NZBxNZW)F1 mice.
Yamauchi T; Ishibashi A; Shikata K; Tokuhara N; Seino K; Kobayashi S; Nagai M
J Pharmacol Exp Ther; 2005 Mar; 312(3):938-44. PubMed ID: 15615868
[TBL] [Abstract][Full Text] [Related]
8. Effects of chenodeoxycholic and ursodeoxycholic acids on interferon-gamma production by peripheral blood mononuclear cells from patients with primary biliary cirrhosis.
Saeki R; Ogino H; Kaneko S; Unoura M; Kobayashi K
J Gastroenterol; 1995 Dec; 30(6):739-44. PubMed ID: 8963391
[TBL] [Abstract][Full Text] [Related]
9. Protective effects of ursodeoxycholic acid on chenodeoxycholic acid-induced liver injury in hamsters.
Iwaki T; Ishizaki K; Kinoshita S; Tanaka H; Fukunari A; Tsurufuji M; Imada T
World J Gastroenterol; 2007 Oct; 13(37):5003-8. PubMed ID: 17854144
[TBL] [Abstract][Full Text] [Related]
10. Immunization with pentraxin 3 (PTX3) leads to anti-PTX3 antibody production and delayed lupus-like nephritis in NZB/NZW F1 mice.
Gatto M; Ghirardello A; Luisetto R; Bassi N; Fedrigo M; Valente M; Valentino S; Del Prete D; Punzi L; Doria A
J Autoimmun; 2016 Nov; 74():208-216. PubMed ID: 27405845
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-21 receptor blockade inhibits secondary humoral responses and halts the progression of preestablished disease in the (NZB × NZW)F1 systemic lupus erythematosus model.
Zhang M; Yu G; Chan B; Pearson JT; Rathanaswami P; Delaney J; Ching Lim A; Babcook J; Hsu H; Gavin MA
Arthritis Rheumatol; 2015 Oct; 67(10):2723-31. PubMed ID: 26097207
[TBL] [Abstract][Full Text] [Related]
12. An Ig mu-heavy chain transgene inhibits systemic lupus erythematosus immunopathology in autoimmune (NZB x NZW)F1 mice.
Wellmann U; Letz M; Schneider A; Amann K; Winkler TH
Int Immunol; 2001 Dec; 13(12):1461-9. PubMed ID: 11717187
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of lupus disease by anti-double-stranded DNA antibodies of the IgM isotype in the (NZB x NZW)F1 mouse.
Werwitzke S; Trick D; Kamino K; Matthias T; Kniesch K; Schlegelberger B; Schmidt RE; Witte T
Arthritis Rheum; 2005 Nov; 52(11):3629-38. PubMed ID: 16255055
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis.
Zoja C; Benigni A; Noris M; Corna D; Casiraghi F; Pagnoncelli M; Rottoli D; Abbate M; Remuzzi G
Kidney Int; 2001 Aug; 60(2):653-63. PubMed ID: 11473648
[TBL] [Abstract][Full Text] [Related]
15. The Ox40/Ox40 Ligand Pathway Promotes Pathogenic Th Cell Responses, Plasmablast Accumulation, and Lupus Nephritis in NZB/W F1 Mice.
Sitrin J; Suto E; Wuster A; Eastham-Anderson J; Kim JM; Austin CD; Lee WP; Behrens TW
J Immunol; 2017 Aug; 199(4):1238-1249. PubMed ID: 28696253
[TBL] [Abstract][Full Text] [Related]
16. Animal models utilized in the research of autoimmune disease control: experimental therapy of glomerulonephritis in NZB/W F1 mice.
Okudaira H; Terada E; Okudaira K
Prog Clin Biol Res; 1987; 229():157-74. PubMed ID: 3601985
[TBL] [Abstract][Full Text] [Related]
17. Retinoic acid reduces autoimmune renal injury and increases survival in NZB/W F1 mice.
Kinoshita K; Yoo BS; Nozaki Y; Sugiyama M; Ikoma S; Ohno M; Funauchi M; Kanamaru A
J Immunol; 2003 Jun; 170(11):5793-8. PubMed ID: 12759464
[TBL] [Abstract][Full Text] [Related]
18. Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferon-gamma receptor inhibits the onset of glomerulonephritis.
Ozmen L; Roman D; Fountoulakis M; Schmid G; Ryffel B; Garotta G
Eur J Immunol; 1995 Jan; 25(1):6-12. PubMed ID: 7843255
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin treatment attenuates proteinuria and prevents weight loss in NZB/W F1 mice.
Paran D; Bernheim J; Golan I; Caspi D; Bernheim J; Benchetrit S
Lupus; 2006; 15(8):526-31. PubMed ID: 16942006
[TBL] [Abstract][Full Text] [Related]
20. UDCA and CDCA alleviate 17α-ethinylestradiol-induced cholestasis through PKA-AMPK pathways in rats.
Li X; Yuan Z; Liu R; Hassan HM; Yang H; Sun R; Zhang L; Jiang Z
Toxicol Appl Pharmacol; 2016 Nov; 311():12-25. PubMed ID: 27743861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
